ARTICLE | Company News

Biogen, TIGET in hemophilia gene therapy tie-up

January 30, 2015 2:46 AM UTC

Biogen Idec Inc. (NASDAQ:BIIB) started a collaboration with Fondazione Telethon (Milano, Italy) and Ospedale San Raffaele (Milano, Italy) to develop gene therapies to treat hemophilia A and B.

Biogen will pay the San Raffaele-Telethon Institute for Gene Therapy (TIGET) $5 million up front and will receive options to license global development and commercialization rights to two hemophilia programs, one in hemophilia A and one in hemophilia B, after clinical proof-of-concept trials. TIGET is eligible for undisclosed development milestones. Biogen will fund the research. ...